logo-loader
viewCello Health PLC

Cello Health expects 'robust' profits growth in first half

With cash in the bank, management are eyeing acquisitions in the US

pharmaceuticals
Cello Health services 24 of the top 25 pharmaceutical clients globally

Healthcare-focused consultancy Cello Health PLC (LON:CLL) is confident its second quarter will continue the “very good” start made to 2019.

Growth in like-for-like net revenue and headline profit before tax in the first quarter was described as “good” in a statement issued ahead of the AIM-listed company’s annual shareholder meeting.

The consulting businesses and the US operations put in an “excellent” performance and are expected to continue this trend in the second quarter.

Last year the company changed its name to Cello Health to reflect the new ongoing strategic focus on the healthcare sector, where it services 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech and medical equipment outfits.

Without mentioning numbers, Cello’s confidence about the second quarter led management to expect headline PBT growth for the first half of the year will be “robust”. Last year, headline PBT increased 6.4% to £12.2mln on revenue up 2.3% to £104.8mln.

Cash conversion has been better than expected, continuing the trend from last year, which finished with £6.3mln in the coffers. Management plan to put some of this cash to use through acquisitions and are assessing suitable growth opportunities in the US.

Chairman Chris Jones was quoted as saying that the year to date has been as expectated and that the board is confident of achieving a successful full year result in 2019, "in line with expectations".

Quick facts: Cello Health PLC

Price: 129.165 GBX

AIM:CLL
Market: AIM
Market Cap: £137.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Cello Health reports good growth in profits and strong cash flow

Cello Health PLC's (LON:CLL) Mark Scott tells Proactive London they've seen good growth in profits and strong cash flow for the first half of the year said that he's confident about the rest of the year too. The group delivered net revenue of £54.5mln for the first six months of the year,...

on 18/9/19

RNS

Holding(s) in Company

1 week, 1 day ago

Total Voting Rights

1 week, 2 days ago

Total Voting Rights

on 7/10/19

Disposal

on 2/10/19

Interim Results

on 18/9/19

Acquisition of ISS

on 16/8/19

2 min read